References:
1. Pascall E, Tulloh RM (2018) Pulmonary hypertension in congenital heart disease. Future Cardiol 14:343–353 . https://doi.org/10.2217/fca-2017-0065
2. Arvanitaki A, Gatzoulis MA, Opotowsky AR, Khairy P, Dimopoulos K, Diller G-P, Giannakoulas G, Brida M, Griselli M, Grünig E, Montanaro C, Alexander PD, Ameduri R, Mulder BJM, D’Alto M (2022) Eisenmenger Syndrome. J Am Coll Cardiol 79:1183–1198 . https://doi.org/10.1016/j.jacc.2022.01.022
3. Xu Z, Gatzoulis MA, Dimopoulos K, Li Q, Zhang C, Keller BB, Gu H (2021) Better Outcomes in Pulmonary Arterial Hypertension After Repair of Congenital Heart Disease, Compared With Idiopathic Pulmonary Arterial Hypertension. CJC Open 3:872–879 . https://doi.org/10.1016/j.cjco.2021.02.010
4. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galie N (2014) Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 35:716–724 . https://doi.org/10.1093/eurheartj/eht072
5. DIaz GF, Marquez A, Ruiz-Parra A, Beghetti M, Ivy D (2021) An Acute Hyperoxia Test Predicts Survival in Children with Pulmonary Hypertension Living at High Altitude. High Alt Med Biol 22:395–405 . https://doi.org/10.1089/ham.2021.0026
6. Smadja DM, Gaussem P, Mauge L, Israël-Biet D, Dignat-George F, Peyrard S, Agnoletti G, Vouhé PR, Bonnet D, Levy M (2009) Circulating endothelial cells. A new candidate biomarker of irreversible pulmonary hypertension secondary to congenital heart disease. Circulation 119:374–381 . https://doi.org/10.1161/CIRCULATIONAHA.108.808246
7. McMurtry MS (2005) Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Invest 115:1479–1491 . https://doi.org/10.1172/JCI23203